Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event

Reuters

2025/05/03

<a href="https://laohu8.com/S/FLGT">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event

Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, "We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025." Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532386458"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532386458\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532386458?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-03 09:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532386458","market":"nz","top_or_hot":-1,"title":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-03 09:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250503:nNDLbwkDF9:1","article_id":"2532386458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532386458","pubTimestamp":1746234431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics Inc.发布2025年第一季度收益看涨期权活动记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n    \n\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}